| Autor: |
Konstantinus, Iyaloo, Chiwara, Douglas, Ndevaetela, Emmy-Else, Ndarukwa-Phiri, Victoria, Garus-oas, Nathalia!, Frans, Ndahafa, Ndumbu, Pentikainen, Shiningavamwe, Andreas, van Rooyen, Gerhard, Schiceya, Ferlin, Hlahla, Lindile, Namundjebo, Pendapala, Ndozi-Okia, Ifeoma, Chikuse, Francis, Bantiewalu, Sirak Hailu, Tjombonde, Kapena |
| Předmět: |
|
| Zdroj: |
PLoS ONE; 9/27/2022, Vol. 17 Issue 9, p1-10, 10p |
| Abstrakt: |
Background: As new SARS-CoV-2 variants of concern emerge, there is a need to scale up testing to minimize transmission of the Coronavirus disease 2019 (COVID-19). Many countries especially those in the developing world continue to struggle with scaling up reverse transcriptase polymerase reaction (RT-PCR) to detect SARS-CoV-2 due to scarcity of resources. Alternatives such as antigen rapid diagnostics tests (Ag-RDTs) may provide a solution to enable countries scale up testing. Methods: In this study, we evaluated the Panbio™ and STANDARD Q Ag-RDTs in the laboratory using 80 COVID-19 RT-PCR confirmed and 80 negative nasopharyngeal swabs. The STANDARD Q was further evaluated in the field on 112 symptomatic and 61 asymptomatic participants. Results: For the laboratory evaluation, both tests had a sensitivity above 80% (Panbio™ = 86% vs STANDARD Q = 88%). The specificity of the Panbio™ was 100%, while that of the STANDARD Q was 99%. When evaluated in the field, the STANDARD Q maintained a high specificity of 99%, however the sensitivity was reduced to 56%. Conclusion: Using Ag-RDTs in low resource settings will be helpful in scaling-up SARS-CoV-2 testing, however, negative results should be confirmed by RT-PCR where possible to rule out COVID-19 infection. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
